Cargando…

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium

Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease, in which several factors combine to give the final clinical expression. Both early and more recent studies have shown that forced expiratory volume in one second (FEV(1)), despite being an extremely important parameter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Campos, Jose Luis, Calero, Carmen, Lopez-Ramirez, Cecilia, Asensio-Cruz, Maria Isabel, Márquez-Martín, Eduardo, Ortega-Ruiz, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303404/ https://www.ncbi.nlm.nih.gov/pubmed/25653503 http://dx.doi.org/10.2147/PPA.S55009

Ejemplares similares

Understanding of COPD among final-year medical students
por: Mohigefer, Javier, et al.
Publicado: (2017)

Clinical use of aclidinium in patients with COPD
por: Reid, Debra J, et al.
Publicado: (2014)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Results from an Audit Feedback Strategy for Chronic Obstructive Pulmonary Disease In-Hospital Care: A Joint Analysis from the AUDIPOC and European COPD Audit Studies
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2014)

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
por: Suppli Ulrik, Charlotte
Publicado: (2012)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

Triple therapy for COPD: a crude analysis from a systematic review of the evidence
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2019)

Inflammatory response in human lung cells stimulated with plasma from COPD patients
por: Arellano-Orden, Elena, et al.
Publicado: (2022)

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
por: Karabis, Andreas, et al.
Publicado: (2014)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD
por: Manoharan, Arvind, et al.
Publicado: (2016)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays
por: López-Campos, José L, et al.
Publicado: (2012)

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison
por: Medic, Goran, et al.
Publicado: (2016)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Predictors of Single Bronchodilation Treatment Response for COPD: An Observational Study with the Trace Database Cohort
por: Hernández, Laura Carrasco, et al.
Publicado: (2021)

Symptom variability in COPD: a narrative review
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2013)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021)

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
por: Koopman, Maud, et al.
Publicado: (2022)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
por: Miravitlles, Marc, et al.
Publicado: (2016)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
por: Monteagudo, Mònica, et al.
Publicado: (2017)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011)

Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2015)

Evaluation of lung parenchyma, blood vessels, and peripheral blood lymphocytes as a potential source of acute phase reactants in patients with COPD
por: Arellano-Orden, Elena, et al.
Publicado: (2019)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2017)

Specific networks of plasma acute phase reactants are associated with the severity of chronic obstructive pulmonary disease: a case-control study
por: Arellano-Orden, Elena, et al.
Publicado: (2017)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
por: Sims, Michael W, et al.
Publicado: (2011)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Zhong, Jun, et al.
Publicado: (2014)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Jones, Paul W
Publicado: (2015)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
por: Singh, Dave, et al.
Publicado: (2014)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
por: Wise, Robert A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_al7ote1rfvrrsjpn1c9es6lued